Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C
Brief Summary: A Phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C
B: Arm Label: Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Arm Label: Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Arm Label: Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks
C: Arm Label: Arm 1: Null or Partial Responder to P/R (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV) | Arm Label: Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV) | Arm Label: Arm 3: Treatment naive (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV), Drug: Pegylated-interferon alfa 2a (PegIFN), Drug: Ribavirin (RBV) | Arm Label: Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week; Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV), Drug: Pegylated-interferon alfa 2a (PegIFN), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: Asunaprevir (ASV); Assigned to Arm(s): Arm 1: Null or Partial Responder to P/R (ASV + DCV), Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV), Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Daclatasvir (DCV); Assigned to Arm(s): Arm 1: Null or Partial Responder to P/R (ASV + DCV), Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV), Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Pegylated-interferon alfa 2a (PegIFN); Assigned to Arm(s): Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week
D: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin | Intervention Type: BIOLOGICAL; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week

Answer: D